covid_cell

Pharmafile.com’s weekly COVID-19 news round-up

pharmafile | June 3, 2020 | News story | Research and Development COVID-19, coronavirus 

COVID-19 treatments dominate the news this week as Russia is set to start its roll out of the anti-viral drug Avifavir to coronavirus patients, while the UK-based Drug Safety Research Unit (DSRU) has reported its findings from the first ever systematic benefit-risk analysis of Gilead’s remdesivir and found the drug to have a tentatively “favourable” profile.

Multiple European countries have also rejected the use of hydroxychloroquine in patients suffering from coronavirus, while the US has given $1 billion to AstraZeneca to advance the development and production of the vaccine they are creating in collaboration with the Oxford University.

1. US donates $1 billion to Oxford University’s COVID-19 vaccine in exchange for 300 million dosesPublished 29/05/20

The US has given $1 billion to AstraZeneca to advance the development and production of the vaccine they are creating in collaboration with the Oxford University.

2. Cleaning staff excluded from GSK’s £1.5k COVID-19 employee bonusPublished on 26/05/20

UK pharma giant GlaxoSmithKline has pledged to pay a cash bonus of £1,500 to staff continuing to work during the COVID-19 pandemic, acknowledging the increased risk they face for maintaining research and production operations during this dangerous time.

3. Russia to begin administering anti-viral COVID-19 drug next weekPublished 01/06/20

Russia will start its roll out of the anti-viral drug Avifavir (favipiravir) to COVID-19 patients next week, according to the Russian Direct Investment Fund (RDIF).

4. European countries reject hydroxychloroquine treatments for COVID-19Published 28/05/2020

Multiple European countries have rejected the use of hydroxychloroquine in patients suffering from coronavirus, due to a lack of evidence that it is effective.

5. First ever benefit-risk analysis is “favourable” for remdesivir as COVID-19 treatmentPublished 29/05/20

The UK-based Drug Safety Research Unit (DSRU) has reported its findings from the first ever systematic benefit-risk analysis of Gilead’s remdesivir, one of the leading hope in the treatment of COVID-19, noting that it found the drug to have a tentatively “favourable” profile.

Related Content

Gilead’s Veklury recommended by NICE for COVID-19 treatment

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …

NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19

The National Institute for Health and Care Excellence (NICE) has announced that it has expanded …

diana-polekhina-zbsthwt9vlc-unsplash_2

Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine

Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational …

Latest content